Drugs / 89Zirconium-M7824
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04297748 | Jun 2020 → Nov 2022 | non-small cell lung carcinoma | Olivia Newton-John Cancer Research Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zirconium-M7824 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04297748 ↗ |
| Modality | Diagnostic / imaging agent | “PET imaging agent” NCT04297748 ↗ |
| Route | Intravenous | “initial trace (100 mg, IV) dose of zirconium-89 (1.8-2.5 mCi) labelled M7824 (89Zr-M7824)” NCT04297748 ↗ |